Factors influencing the allergenicity and adjuvanticity of allergens

Immunotherapy

Volumn 3, Issue 7, 2011, Pages 881-893

  Deifl, Stephan ^a   Bohle, Barbara ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

adjuvants; allergen; allergen specific immunotherapy; allergenicity; allergy; vaccine design

Indexed keywords

ALLERGEN; ALUMINUM POTASSIUM SULFATE; BET V 1; FLAGELLIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; LIPID BINDING PROTEIN; OVALBUMIN; PATTERN RECOGNITION RECEPTOR; POLYMYXIN B; RECOMBINANT ALLERGEN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AIRWAY OBSTRUCTION; ALLERGENICITY; ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ASTHMA; CONJUNCTIVITIS; DENDRITIC CELL; DIMERIZATION; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; OLIGOMERIZATION; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; RHINITIS; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; TH2 CELLS;

EID: 79960499707     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.69     Document Type: Review

References (117)

1. Renkonen J, Mattila P, Lehti S et al. Birch pollen allergen Bet v 1 binds to and is transported through conjunctival epithelium in allergic patients. Allergy 64(6), 868-875 (2009).
2. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33(5), 1205-1214 (2003).
3. + T cells derived from the majority of atopic donors are able to suppress Th1 and Th2 cytokine production. J. Allergy Clin. Immunol. 111(4), 862-868 (2003).
4. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94(2), 870-876 (1994).
5. + T cell clones derived from a patient with severe atopic disease. Int. J. Clin. Lab. Res. 21(2), 186-189 (1991).
6. Bodey KJ, Semper AE, Redigton AE et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 54(10), 1083-1093 (1999).
7. Schulten V, Radakovics A, Hartz C et al. Characterization of the allergic T-cell response to Pru p 3, the nonspecific lipid transfer protein in peach. J. Allergy Clin. Immunol. 124(1), 100-107 (2009).
8. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145(11), 3796-3806 (1990).
9. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int. Arch. Allergy Immunol. 141(2), 119-129 (2006).
10. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 181(3), 1081-1089 (1995).
11. Lindell DM, Berlin AA, Schaller MA, Lukacs NW. B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease. PLoS One 3(9), E3129 (2008).
12. Durham SR. Mechanisms of mucosal inflammation in the nose and lungs. Clin. Exp. Allergy 28(Suppl. 2), 11-16 (1998).
13. Okada M, Terui T, Honda M et al. Cutaneous late phase reaction in adult atopic dermatitis patients with high serum IgE antibody to Dermatophagoides farinae: correlation with IL-5 production by allergen-stimulated peripheral blood mononuclear cells. J. Dermatol. Sci. 29(2), 73-84 (2002).
14. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189(12), 1885-1894 (1999).
15. Larche M, Haselden BM, Oldfield WL et al. Mechanisms of T cell peptide epitope-dependent late asthmatic reactions. Int. Arch. Allergy Immunol. 124(1-3), 272-275 (2001).
16. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 127(4), 450-458 (2009).
17. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy DOI: 10.1111/j.1398-9995.2011.02576.x (2011) (Epub ahead of print).
18. Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81(5 Pt 1), 401-405 (1998).
19. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir. Med. 103(6), 800-812 (2009).
20. Calderon MA, Casale TB, Togias A et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J. Allergy Clin. Immunol. 127(1), 30-38 (2011).
21. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6(10), 761-771 (2006).
22. James LK, Shamji MH, Walker SM et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J. Allergy Clin. Immunol. 127(2), 509-516.e5 (2011).
23. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27(9), 1007-1015 (1997).
24. Mobs C, Slotosch C,Loffler H et al. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J. Immunol. 184(4), 2194-2203 (2010).
25. + T cells expressing peripheral tissue trafficking markers. Clin. Exp. Allergy 34(8), 1209-1219 (2004).
26. Durham SR. The inflammatory nature of allergic disease. Clin. Exp. Allergy 28(Suppl. 6), 20-24 (1998).
27. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13(6), 603-609 (1999).
28. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172(5), 3252-3259 (2004).
29. + cells in the nasal mucosa. J. Allergy Clin. Immunol. 121(6), 1467-1472, 1472.E1 (2008).
30. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121(5), 1120-1125 e1122 (2008).
31. Pilette C, Nouri-Aria KT, Jacobson MR et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. J. Immunol. 178(7), 4658-4666 (2007).
32. Wurtzen PA, Lund G, Lund K et al. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin. Exp. Allergy 38(8), 1290-1301 (2008).
33. Mari A, Iacovacci P, Afferni C et al. Specific IgE to cross-reactive carbohydrate determinants strongly affect the in vitro diagnosis of allergic diseases. J. Allergy Clin. Immunol. 103(6), 1005-1011 (1999).
34. Mari A. IgE to cross-reactive carbohydrate determinants: analysis of the distribution and appraisal of the in vivo and in vitro reactivity. Int. Arch. Allergy Immunol. 129(4), 286-295 (2002).
35. Foetisch K, Westphal S, Lauer I et al. Biological activity of IgE specific for cross-reactive carbohydrate determinants. J. Allergy Clin. Immunol. 111(4), 889-896 (2003).
36. Emanuelsson C, Spangfort MD. Allergens as eukaryotic proteins lacking bacterial homologues. Mol. Immunol. 44(12), 3256-3260 (2007).
37. Wan H, Winton HL, Soeller C et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Invest. 104(1), 123-133 (1999).
38. Shakib F, Schulz O, Sewell H. A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity. Immunol. Today. 19(7), 313-316 (1998).
39. Furmonaviciene R, Ghaemmaghami AM, Boyd SE et al. The protease allergen Der p 1 cleaves cell surface DC-SIGN and DC-SIGNR: experimental analysis of in silico substrate identification and implications in allergic responses. Clin. Exp. Allergy 37(2), 231-242 (2007).
40. Ebeling C, Lam T, Gordon JR, Hollenberg MD, Vliagoftis H. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. J. Immunol. 179(5), 2910-2917 (2007).
41. Jeong SK, Kim HJ, Youm JK et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J. Invet. Dermatol. 128(8), 1930-1939 (2008).
42. Kato T, Takai T, Fujimura T et al. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. Allergy 64(9), 1366-1374 (2009).
43. Asokananthan N, Graham PT, Stewart DJ et al. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J. Immunol. 169(8), 4572-4578 (2002).
44. Adam E, Hansen KK, Astudillo Fernandez O et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2- independent mechanism. J. Biol. Chem. 281(11), 6910-6923 (2006).
45. Deb R, Shakib F, Reid K, Clark H. Major house dust mite allergens Dermatophagoides pteronyssinus 1 and Dermatophagoides farinae 1 degrade and inactivate lung surfactant proteins A and D. J. Biol. Chem. 282(51), 36808-36819 (2007).
46. Gough L, Campbell E, Bayley D, Van Heeke G, Shakib F. Proteolytic activity of the house dust mite allergen Der p 1 enhances allergenicity in a mouse inhalation model. Clin. Exp. Allergy 33(8), 1159-1163 (2003).
47. Yu HS, Angkasekwinai P, Chang SH, Chung Y, Dong C. Protease allergens induce the expression of IL-25 via Erk and p38 MAPK pathway. J. Korean Med. Sci. 25(6), 829-834 (2010).
48. Chapman MD, Wunschmann S, Pomes A. Proteases as Th2 adjuvants. Curr. Allergy Asthma Rep. 7(5), 363-367 (2007).
49. Phillips C, Coward WR, Pritchard DI, Hewitt CR. Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites. J. Leukoc. Biol. 73(1), 165-171 (2003).
50. Sokol CL, Chu NQ, Yu S et al. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat. Immunol. 10(7), 713-720 (2009).
51. Sokol CL, Medzhitov R. Role of basophils in the initiation of Th2 responses. Curr. Opin. Immunol. 22(1), 73-77 (2010).
52. Rabensteiner DF, Spreitzhofer E, Trummer G et al. Pollen enzymes degrade human tear fluid and conjunctival cells: an approach to understanding seasonal non-allergic conjunctivitis. Dev. Ophthalmol. 45, 83-92 (2010).
53. Ichikawa S, Takai T, Yashiki T et al. Lipopolysaccharide binding of the mite allergen Der f 2. Genes Cells 14(9), 1055-1065 (2009).
54. Mueller GA, Edwards LL, Aloor JJ et al. The structure of the dust mite allergen Der p 7 reveals similarities to innate immune proteins. J. Allergy Clin. Immunol. 125(4), 909-917.E4 (2010).
55. Epton MJ, Dilworth RJ, Smith W, Thomas WR. Sensitisation to the lipid-binding apolipophorin allergen Der p 14 and the peptide Mag-1. Int. Arch. Allergy Immunol. 124(1-3), 57-60 (2001).
56. Gonzalez-Rioja R, Asturias JA, Martinez A, Goni FM, Viguera AR. Par j 1 and Par j 2, the two major allergens in Parietaria judaica, bind preferentially to monoacylated negative lipids. FEBS J. 276(6), 1762-1775 (2009).
57. Salcedo G, Sanchez-Monge R, Barber D, Diaz-Perales A. Plant non-specific lipid transfer proteins: an interface between plant defence and human allergy. Biochim. Biophys. Acta 1771(6), 781-791 (2007).
58. Spangfort MD, Mirza O, Ipsen H et al. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by x-ray crystallography and site-directed mutagenesis. J. Immunol. 171(6), 3084-3090 (2003).
59. Mognsen JE, Wimmer R, Larsen JN, Spangfort MD, Otzen DE. The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands. J. Biol. Chem. 277(26), 23684-23692 (2002).
60. Chisholm D, Libet L, Hayashi T, Horner AA. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J. Allergy Clin. Immunol. 113(3), 448-454 (2004).
61. Redecke V, Hacker H, Datta SK et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 172(5), 2739-2743 (2004).
62. Eisenbarth SC, Piggott DA, Huleatt JW et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 196(12), 1645-1651 (2002).
63. Tan AM, Chen HC, Pochard P et al. TLR4 signaling in stromal cells is critical for the initiation of allergic Th2 responses to inhaled antigen. J. Immunol. 184(7), 3535-3544 (2010).
64. Gilles S, Mariani V, Bryce M et al. Pollen allergens do not come alone: pollen associated lipid mediators (PALMS) shift the human immune systems towards a Th2-dominated response. Allergy Asthma Clin. Immunol. 5(1), 3 (2009).
65. Traidl-Hoffmann C, Mariani V, Hochrein H et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. 201(4), 627-636 (2005).
66. Gilles S, Mariani V, Bryce M et al. Pollen-derived E1-phytoprostanes signal via PPAR-g and NF-kB-dependent mechanisms. J. Immunol. 182(11), 6653-6658 (2009).
67. + dendritic cells' capacity to induce T-helper type 1 responses. Clin. Exp. Allergy 40(2), 269-278 (2010).
68. Gruber A, Mancek M, Wagner H, Kirschning CJ, Jerala R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J. Biol. Chem. 279(27), 28475-28482 (2004).
69. Keber MM, Gradisar H, Jerala R. MD-2 and Der p 2 - a tale of two cousins or distant relatives? J. Endotoxin Res. 11(3), 186-192 (2005).
70. Trompette A, Divanovic S, Visintin A et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 457(7229), 585-588 (2009).
71. van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeek TB. Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr. Opin. Immunol. 16(4), 488-493 (2004).
72. den Dunnen J, Gringhuis SI, Geijtenbeek TB. Dusting the sugar fingerprint: C-type lectin signaling in adaptive immunity. Immunol. Lett. 128(1), 12-16 (2010).
73. Shreffler WG, Castro RR, Kucuk ZY et al. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J. Immunol. 177(6), 3677-3685 (2006).
74. Hsu SC, Chen CH, Tsai SH et al. Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells. J. Biol. Chem. 285(11), 7903-7910 (2010).
75. Royer PJ, Emara M, Yang C et al. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J. Immunol. 185(3), 1522-1531 (2010).
76. Niemi M, Jylha S, Laukkanen M.L. et al. Molecular interactions between a recombinant IgE antibody and the b-lactoglobulin allergen. Structure 15(11), 1413-141 (2007).
77. Rouvinen J, Janis J, Laukkanen ML et al. Transient dimers of allergens. PLoS One 5(2), E9037 (2010).
78. Li M, Gustchina A, Alexandratos J et al. Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody. J. Biol. Chem. 283(33), 22806-22814 (2008).
79. Lascombe MB, Gregoire C, Poncet P et al. Crystal structure of the allergen Equ c 1. A dimeric lipocalin with restricted IgE-reactive epitopes. J. Biol. Chem. 275(28), 21572-21577 (2000).
80. Verdino P, Westritschnig K, Valenta R, Keller W. The cross-reactive calcium-binding pollen allergen, Phl p 7, reveals a novel dimer assembly. EMBO J. 21(19), 5007-5016 (2002).
81. Rajashankar K, Bufe A, Weber W et al. Structure of the functional domain of the major grass-pollen allergen Phlp 5b. Acta Crystallogr. D Biol. Crystallogr. 58(Pt 7), 1175-1181 (2002).
82. van Oort E, Dieker MC, de Heer PG et al. The major grass pollen group 5 allergen from Dactylis glomerata and its C-terminal split product both behave as dimers: implications for allergen standardization. Int. Arch. Allergy Immunol. 136(2), 113-122 (2005).
83. Magler I, Nuss D, Hauser M, Ferreira F, Brandstetter H. Molecular metamorphosis in polcalcin allergens by EF-hand rearrangements and domain swapping. FEBS J. 277(12), 2598-2610 (2010).
84. Wopfner N, Dissertori O, Ferreira F, Lackner P. Calcium-binding proteins and their role in allergic diseases. Immunol. Allergy Clin. North Am. 27(1), 29-44 (2007).
85. Scholl I, Kalkura N, Shedziankova Y et al. Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. J. Immunol. 175(10), 6645-6650 (2005).
86. Zaborsky N, Brunner M, Wallner M et al. Antigen aggregation decides the fate of the allergic immune response. J. Immunol. 184(2), 725-735 (2010).
87. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008).
88. Kool M, Petrilli V, De Smedt T et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181(6), 3755-3759 (2008).
89. Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38(8), 2085-2089 (2008).
90. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy 34(9), 1373-1378 (2004).
91. Casale TB, Stokes JR. Future forms of immunotherapy. J. Allergy Clin. Immunol. 127(1), 8-15; quiz 16-17 (2011).
92. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60(5), 678-684 (2005).
93. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33(9), 1198-1208 (2003).
94. Rosewich M, Schulze J, Eickmeier O et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin. Exp. Immunol. 160(3), 403-410 (2010).
95. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
96. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon g. Proc. Natl Acad. Sci. USA 93(7), 2879-2883 (1996).
97. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA 96(16), 9305-9310 (1999).
98. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-g production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol. 29(7), 2344-2353 (1999).
99. Tighe H, Takabayashi K, Schwartz D et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106(1 Pt 1), 124-134 (2000).
100. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1445-1455 (2006).
101. Mutschlechner S, Deifl S, Bohle B. Genetic allergen modification in the development of novel approaches to specific immunotherapy. Clin. Exp. Allergy 39(11), 1635-1642 (2009).
102. Bublin M, Hoflehner E, Wagner B et al. Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25(50), 8395-8404 (2007).
103. Lee BK, Yoo YG, Lee WY et al. Ovalbumin fused with diphtheria toxin protects mice from ovalbumin induced anaphylactic shock. Yonsei Med. J. 42(1), 91-105 (2001).
104. Sleytr UB, Bayley H, Sara M et al. Applications of S-layers. FEMS Microbiol. Rev. 20(1-2), 151-175 (1997).
105. Breitwieser A, Egelseer EM, Moll D et al. A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen. Protein Eng. 15(3), 243-249 (2002).
106. Bohle B, Breitwieser A, Zwolfer B et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172(11), 6642-6648 (2004).
107. Gerstmayr M, Ilk N, Jahn-Schmid B, Sleytr UB, Bohle B. Natural self-assembly of allergen-S-layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity. Int. Arch. Allergy Immunol. 149(3), 231-238 (2009).
108. Gerstmayr M, Ilk N, Schabussova I et al. A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J. Immunol. 179(11), 7270-7275 (2007).
109. Ilk N, Schumi CT, Bohle B, Egelseer EM, Sleytr UB. Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy. Microb. Cell Fact. 10(1), 6 (2011).
110. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832), 1099-1103 (2001).
111. Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201-214 (2008).
112. McDonald WF, Huleatt JW, Foellmer HG et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195(11), 1607-1617 (2007).
113. Lee SE, Koh YI, Kim MK et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J. Clin. Immunol. 28(2), 157-165 (2008).
114. Schulke S, Waibler Z, Mende MS et al. Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC. Mol. Immunol. 48(1-3), 341-350 (2010).
115. Fili L, Ferri S, Guarna F et al. Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J. Allergy Clin. Immunol. 118(2), 511-517 (2006).
116. Vultaggio A, Nencini F, Fitch PM et al. Modified adenine (9-benzyl-2-butoxy-8- hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J. Immunol. 182(2), 880-889 (2009).
117. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 15(11), 2045-2047 (2001).